News

Global Health EDCTP Prizes 2025: applications are now open

Published on | 1 month ago

Programmes Health

The EDCTP Prizes are open for submissions from 11 March until 1 April 2025 via the Funding and Tenders Portal. Deadline to apply is on 1 April, 17:00 CET.

The EDCTP Prizes will recognise outstanding individuals and research teams from Africa and Europe who have made significant achievements in their research field. Additionally, the awardees will have made major contributions to strengthening clinical research capacity in Africa and supporting South-South and North-South networking. The Prizes will be awarded during the Twelfth EDCTP Forum, taking place on 15-20 June 2025 in Kigali, Rwanda.

Contrary to previous editions, applications for the EDCTP Prizes 2025 are to be submitted by the individuals or teams applying for the Prizes, with supporting letter(s) of recommendation from at least one reputable scientist.

Find out more on the dedicated EDCTP3 webpage and read the Rules of Contest.


The Global Health EDCTP3 Joint Undertaking (GH EDCTP3 JU) is a partnership between the European Union and the European and Developing Countries Clinical Trials Partnership (EDCTP) Association whose members are several EU Member States and Associated countries and several African countries.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1602 articles available search in articles 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.